As per the research report, the size of the Asia Pacific Competent Cells Market is valued at USD 0.35 billion in 2020 and estimated to grow at a CAGR of 11.92%, to reach USD 0.62 billion by 2025 during the forecast period 2020-2025.
The Asia Pacific Competent Cells market is developing at an exceptionally quick pace. Transformation is a method of horizontal gene transfer by which some microbes take up exterior genetic material (i.e. uncovered DNA) from the surroundings. The prerequisite for microbes to undergo transformation is its capability to take up open, extracellular genetic material. Such microorganisms are termed as competent cells.
Progresses in molecular cloning investigation is because of the introduction of new machinery and the increasing marketable demand for atomic cloned products and recombinant proteins are some the key force driving the growth of this market. Though the growing market association is creating entry barriers and the enormous cost of competent cells setups is limiting the progress of this market.
This research report segmented and sub-segmented into the following categories:
Cloning is estimated to command the major share of this market in 2017. Increasing study on cloning, driven by government funding is among the major reasons driving market growth in this segment. In 2016, the academic research institutes segment is likely to have for the largest share of the market.
China and India are likely to increase the market because of a huge population. Also the Asia Pacific is largest growing segment.
The Top companies leading in the APAC Competent Cells Market profiled in the report are BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Merck KGaA (Germany), Promega Corporation (U.S.), Bioline (U.K.), Zymo Research (U.S.),are the leaders in the Asia Pacific Competent Cells market.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Chemically
5.1.2 Electrocompetent
5.1.3 Y-o-Y Growth Analysis, By Type
5.1.4 Market Attractiveness Analysis, By Type
5.1.5 Market Share Analysis, ByType
5.2 Application
5.2.1 Cloning
5.2.1.1 Subcloning & Routine Cloning
5.2.1.2 Phage Display Library Construction
5.2.1.3 Toxic/Unstable Dna Cloning
5.2.1.4 High-Throughput Cloning
5.2.2 Protein Expression
5.2.3 Other Applications
5.2.3.1 Mutagenesis
5.2.3.2 Large Plasmid Transformation
5.2.3.4 Single-Stranded Dna Production
5.2.3.5 Lentiviral Vector Production
5.2.7 Y-o-Y Growth Analysis, By Application
5.2.8 Market Attractiveness Analysis, By Application
5.2.9 Market Share Analysis, By Application
5.3 End User
5.3.1 Pharmaceutical Companies
5.3.2 Academia
5.3.3 Y-o-Y Growth Analysis, By EndUser
5.3.4 Market Attractiveness Analysis, By EndUser
5.3.5 Market Share Analysis, By EndUser
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Application
6.1.3.4 By EndUser
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Application
6.1.4.4 By EndUser
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Application
6.1.5.4 By EndUser
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 BioDynamics Laboratory, Inc. (Japan)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GCC Biotech (India)
8.3 SMOBIO Technology (Taiwan)
8.4 Thermo Fisher Scientific, Inc. (U.S)
8.5 QIAGEN N.V. (Germany)
8.6 OriGene Technologies (U.S.)
8.7 Merck KGaA (Germany)
8.8 Promega Corporation (U.S.)
8.9 Bioline (U.K.)
8.10 Zymo Research (U.S.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
